{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:12:30Z","timestamp":1784139150721,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40123-026-01329-w","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:11:36Z","timestamp":1770466296000},"page":"925-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Burden of Delayed Diabetic Retinopathy Management and Use of Artificial Intelligence-Driven Screening Tools: A Systematic Literature Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Firas","family":"Rahhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munia","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"11","key":"1329_CR1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, et\u00a0al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580\u201391.","journal-title":"Ophthalmology"},{"issue":"8","key":"1329_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","volume":"141","author":"EA Lundeen","year":"2023","unstructured":"Lundeen EA, Burke-Conte Z, Rein DB, Wittenborn JS, Saaddine J, et\u00a0al. Prevalence of diabetic retinopathy in the US in 2021. JAMA Ophthalmol. 2023;141(8):747\u201354.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"1329_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7861\/clinmed.2021-0792","volume":"22","author":"THM Fung","year":"2022","unstructured":"Fung THM, Patel B, Wilmot EG, Amoaku WMK. Diabetic retinopathy for the non-ophthalmologist. Clin Med. 2022;22(2):112\u20136.","journal-title":"Clin Med"},{"issue":"2","key":"1329_CR4","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"JD Steinmetz","year":"2021","unstructured":"Steinmetz JD, Bourne RRA, Briant PS, Flaxman SR, Taylor HRB, et\u00a0al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144\u201360.","journal-title":"Lancet Glob Health"},{"key":"1329_CR5","unstructured":"CDC (2024) Why eye exams are important. https:\/\/www.cdc.gov\/vision-health\/about-eye-disorders\/why-eye-exams-are-important.html. Last updated: May 15, 2024. Accessed 8 May 2025."},{"issue":"5","key":"1329_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.survophthal.2018.04.003","volume":"63","author":"H Safi","year":"2018","unstructured":"Safi H, Safi S, Hafezi-Moghadam A, Ahmadieh H. Early detection of diabetic retinopathy. Surv Ophthalmol. 2018;63(5):601\u20138.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"1329_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198979","volume":"14","author":"M Piyasena","year":"2019","unstructured":"Piyasena M, Murthy GVS, Yip JLY, Gilbert C, Zuurmond M, et\u00a0al. Systematic review on barriers and enablers for access to diabetic retinopathy screening services in different income settings. PLoS ONE. 2019;14(4):e0198979.","journal-title":"PLoS ONE"},{"key":"1329_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237120","author":"D Patel","year":"2022","unstructured":"Patel D, Ananthakrishnan A, Lin T, Channa R, Liu TYA, et\u00a0al. Social determinants of health and impact on screening, prevalence, and management of diabetic retinopathy in adults: a narrative review. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11237120.","journal-title":"J Clin Med"},{"key":"1329_CR9","doi-asserted-by":"publisher","DOI":"10.5888\/pcd13.160193","volume":"13","author":"Y Lu","year":"2016","unstructured":"Lu Y, Serpas L, Genter P, Anderson B, Campa D, et\u00a0al. Divergent perceptions of barriers to diabetic retinopathy screening among patients and care providers, Los Angeles, California, 2014-2015. Prev Chronic Dis. 2016;13:E140.","journal-title":"Prev Chronic Dis"},{"issue":"12","key":"1329_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamaophthalmol.2023.5287","volume":"141","author":"R Ravindranath","year":"2023","unstructured":"Ravindranath R, Bernstein IA, Fernandez KS, Ludwig CA, Wang SY. Social determinants of health and perceived barriers to care in diabetic retinopathy screening. JAMA Ophthalmol. 2023;141(12):1161\u201371.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"1329_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3803\/EnM.2023.1913","volume":"39","author":"M Kong","year":"2024","unstructured":"Kong M, Song SJ. Artificial intelligence applications in diabetic retinopathy: what we have now and what to expect in the future. Endocrinol Metab (Seoul). 2024;39(3):416\u201324.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"7","key":"1329_CR12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.4103\/ijo.IJO_1989_18","volume":"67","author":"SK Padhy","year":"2019","unstructured":"Padhy SK, Takkar B, Chawla R, Kumar A. Artificial intelligence in diabetic retinopathy: a natural step to the future. Indian J Ophthalmol. 2019;67(7):1004\u20139.","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"1329_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100228","volume":"3","author":"JI Lim","year":"2023","unstructured":"Lim JI, Regillo CD, Sadda SR, Ipp E, Bhaskaranand M, et\u00a0al. Artificial intelligence detection of diabetic retinopathy: subgroup comparison of the EyeArt system with ophthalmologists\u2019 dilated examinations. Ophthalmol Sci. 2023;3(1):100228.","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"1329_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et\u00a0al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"1329_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1329_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, et\u00a0al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1329_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377\u201384.","journal-title":"J Epidemiol Community Health"},{"issue":"7052","key":"1329_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275\u201383.","journal-title":"BMJ"},{"key":"1329_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0318-x","volume":"16","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, de la Riva-Fernandez S, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, et\u00a0al. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. BMC Ophthalmol. 2016;16:136.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1329_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2024.100071","volume":"13","author":"Y-C Chung","year":"2024","unstructured":"Chung Y-C, Kao Y-W, Huang Y-C, Chen P-E, Liao S-C, et\u00a0al. Cost-effectiveness of diabetic retinopathy screening for newly diagnosed type 2 diabetic patients: a nationwide population-based propensity score-matched cohort study. Asia-Pac J Ophthalmol. 2024;13(3):100071.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"2","key":"1329_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15164","volume":"41","author":"J Brodie","year":"2024","unstructured":"Brodie J, Misra A, Jones CD, Jenkins C, Bachmann MO. Is diabetic retinopathy screening worthwhile among people first diagnosed with diabetes at older ages? A cohort study of Norfolk diabetic retinopathy screening programme. Diabet Med. 2024;41(2):e15164.","journal-title":"Diabet Med"},{"issue":"7","key":"1329_CR22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/dme.13129","volume":"33","author":"G Scotland","year":"2016","unstructured":"Scotland G, McKeigue P, Philip S, Leese GP, Olson JA, et\u00a0al. Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. Diabet Med. 2016;33(7):886\u201395.","journal-title":"Diabet Med"},{"issue":"16","key":"1329_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1612836","volume":"376","author":"DM Nathan","year":"2017","unstructured":"Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, et\u00a0al. Frequency of evidence-based screening for retinopathy in type 1 diabetes. N Engl J Med. 2017;376(16):1507\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"1329_CR24","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s00125-020-05239-9","volume":"63","author":"S Emamipour","year":"2020","unstructured":"Emamipour S, van der Heijden AAWA, Nijpels G, Elders P, Beulens JWJ, et\u00a0al. A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspective. Diabetologia. 2020;63(11):2452\u201361.","journal-title":"Diabetologia"},{"issue":"1","key":"1329_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00125-020-05313-2","volume":"64","author":"DM Broadbent","year":"2021","unstructured":"Broadbent DM, Wang A, Cheyne CP, James M, Lathe J, et\u00a0al. Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT. Diabetologia. 2021;64(1):56\u201369.","journal-title":"Diabetologia"},{"issue":"7","key":"1329_CR26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/dme.12957","volume":"33","author":"PH Scanlon","year":"2016","unstructured":"Scanlon PH, Stratton IM, Leese GP, Bachmann MO, Land M, et\u00a0al. Screening attendance, age group and diabetic retinopathy level at first screen. Diabet Med. 2016;33(7):904\u201311.","journal-title":"Diabet Med"},{"issue":"4","key":"1329_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/dme.12313","volume":"31","author":"PH Scanlon","year":"2014","unstructured":"Scanlon PH, Aldington SJ, Stratton IM. Delay in diabetic retinopathy screening increases the rate of detection of referable diabetic retinopathy. Diabet Med. 2014;31(4):439\u201342.","journal-title":"Diabet Med"},{"key":"1329_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.09.051","volume":"223","author":"M Ohlhausen","year":"2021","unstructured":"Ohlhausen M, Payne C, Greenlee T, Chen AX, Conti T, et\u00a0al. Impact and characterization of delayed pan-retinal photocoagulation in proliferative diabetic retinopathy. Am J Ophthalmol. 2021;223:267\u201374.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1329_CR29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41433-019-0647-0","volume":"34","author":"K-Y Luu","year":"2020","unstructured":"Luu K-Y, Akhter MM, Durbin-Johnson BP, Moshiri A, Tran S, et\u00a0al. Real-world management and long-term outcomes of diabetic macular oedema with good visual acuity. Eye. 2020;34(6):1108\u201315.","journal-title":"Eye"},{"issue":"10","key":"1329_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.oret.2020.12.020","volume":"5","author":"W Song","year":"2021","unstructured":"Song W, Singh RP, Rachitskaya AV. The effect of delay in care among patients requiring intravitreal injections. Ophthalmol Retina. 2021;5(10):975\u201380.","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"1329_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3341\/kjo.2022.0147","volume":"37","author":"BE Ahearn","year":"2023","unstructured":"Ahearn BE, Nguyen H, Sohn JH. Proliferative diabetic retinopathy requiring vitrectomy over clinic management during COVID-19: impact of delayed care. Korean J Ophthalmol. 2023;37(4):292\u20138.","journal-title":"Korean J Ophthalmol"},{"key":"1329_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2021.102449","volume":"35","author":"MN Bulut","year":"2021","unstructured":"Bulut MN, S\u00f6nmez HS, G\u00f6k\u00e7e G, A\u011fa\u00e7kesen A, Bulut K, et\u00a0al. The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown. Photodiagnosis Photodyn Ther. 2021;35:102449.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"2","key":"1329_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247161","volume":"16","author":"AV Naravane","year":"2021","unstructured":"Naravane AV, Mundae R, Zhou Y, Santilli C, van Kuijk F, et\u00a0al. Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: a pilot study. PLoS ONE. 2021;16(2):e0247161.","journal-title":"PLoS ONE"},{"issue":"1","key":"1329_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3928\/23258160-20151214-05","volume":"47","author":"JM Fassbender","year":"2016","unstructured":"Fassbender JM, Ozkok A, Canter H, Schaal S. A comparison of immediate and delayed vitrectomy for the management of vitreous hemorrhage due to proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2016;47(1):35\u201341.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"12","key":"1329_CR35","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1097\/IAE.0000000000003276","volume":"41","author":"RB Rush","year":"2021","unstructured":"Rush RB, Rush SW. Outcomes in patients resuming intravitreal anti-vascular endothelial growth factor therapy following treatment delay during the coronavirus-19 pandemic. Retina. 2021;41(12):2456\u201361.","journal-title":"Retina"},{"issue":"1","key":"1329_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000527942","volume":"246","author":"N Gomel","year":"2023","unstructured":"Gomel N, Shor R, Lippin N, Segal O, Greenbaum E, et\u00a0al. COVID-19 pandemic lockdowns\u2019 impact on visual acuity of diabetic macular edema: a large cohort. Ophthalmologica. 2023;246(1):1\u20138.","journal-title":"Ophthalmologica"},{"issue":"5","key":"1329_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3928\/23258160-20210429-02","volume":"52","author":"F Hentati","year":"2021","unstructured":"Hentati F, Melo AGR, Greenlee TE, Muste J, Chen AX, et\u00a0al. Management of patients with DME with good visual acuity in routine clinical practice. Ophthalmic Surg Lasers Imaging Retina. 2021;52(5):247\u201356.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"1329_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/1932296820967011","volume":"16","author":"SD Fuller","year":"2022","unstructured":"Fuller SD, Hu J, Liu JC, Gibson E, Gregory M, et\u00a0al. Five-year cost-effectiveness modeling of primary care-based, nonmydriatic automated retinal image analysis screening among low-income patients with diabetes. J Diabetes Sci Technol. 2022;16(2):415\u201327.","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"1329_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3928\/23258160-20230406-01","volume":"54","author":"H Chawla","year":"2023","unstructured":"Chawla H, Uhr JH, Williams JS, Reinoso MA, Weiss JS. Economic evaluation of artificial intelligence systems versus manual screening for diabetic retinopathy in the United States. Ophthalmic Surg Lasers Imaging Retina. 2023;54(5):272\u201380.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"1329_CR40","doi-asserted-by":"publisher","DOI":"10.2196\/41624","volume":"9","author":"S Lin","year":"2023","unstructured":"Lin S, Ma Y, Xu Y, Lu L, He J, et\u00a0al. Artificial intelligence in community-based diabetic retinopathy telemedicine screening in urban China: cost-effectiveness and cost-utility analyses with real-world data. JMIR Public Health Surveill. 2023;9:e41624.","journal-title":"JMIR Public Health Surveill"},{"issue":"11","key":"1329_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291390","volume":"18","author":"H Li","year":"2023","unstructured":"Li H, Li G, Li N, Liu C, Yuan Z, et\u00a0al. Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in rural China based on the Markov model. PLoS ONE. 2023;18(11):e0291390.","journal-title":"PLoS ONE"},{"issue":"1","key":"1329_CR42","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12913-022-07655-6","volume":"22","author":"X-M Huang","year":"2022","unstructured":"Huang X-M, Yang B-F, Zheng W-L, Liu Q, Xiao F, et\u00a0al. Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China. BMC Health Serv Res. 2022;22(1):260.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"1329_CR43","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S2589-7500(20)30060-1","volume":"2","author":"Y Xie","year":"2020","unstructured":"Xie Y, Nguyen QD, Hamzah H, Lim G, Bellemo V, et\u00a0al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digit Health. 2020;2(5):e240\u20139.","journal-title":"Lancet Digit Health"},{"issue":"12","key":"1329_CR44","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1016\/j.jval.2023.09.735","volume":"26","author":"K Mansouri","year":"2023","unstructured":"Mansouri K, Nait Atmane R, Taibi A, Ait Mouloud N, Oulmane N, et\u00a0al. EE469 diabetic retinopathy in Algeria: costs estimation and medical-economic value of automated methods AI-based in early screening. Value Health. 2023;26(12):S141\u20132.","journal-title":"Value Health"},{"issue":"1","key":"1329_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40942-024-00547-3","volume":"10","author":"M Karabeg","year":"2024","unstructured":"Karabeg M, Petrovski G, Hertzberg SNW, Erke MG, Fosmark DS, et\u00a0al. A pilot cost-analysis study comparing AI-based EyeArt\u00ae and ophthalmologist assessment of diabetic retinopathy in minority women in Oslo, Norway. Int J Retina Vitreous. 2024;10(1):40.","journal-title":"Int J Retina Vitreous"},{"key":"1329_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102387","volume":"67","author":"W Hu","year":"2024","unstructured":"Hu W, Joseph S, Li R, Woods E, Sun J, et\u00a0al. Population impact and cost-effectiveness of artificial intelligence-based diabetic retinopathy screening in people living with diabetes in Australia: a cost effectiveness analysis. EClinicalMedicine. 2024;67:102387.","journal-title":"EClinicalMedicine"},{"key":"1329_CR47","first-page":"82","volume":"312","author":"SR Chakravarthy","year":"2024","unstructured":"Chakravarthy SR, Mugambi D, Keshavjee K. AI can improve the economics of blindness prevention in Canada. Stud Health Technol Inform. 2024;312:82\u20136.","journal-title":"Stud Health Technol Inform"},{"issue":"8","key":"1329_CR48","first-page":"5433","volume":"64","author":"SP Harding","year":"2023","unstructured":"Harding SP, Wang Z, So C, Chen X, McGhee S, et\u00a0al. Impact on blindness of organized diabetic retinopathy screening including artificial intelligence (AI) and optical coherence tomography (OCT) in urban China\u2014A lifetime cost-effectiveness analysis (CEA). Investig Ophthalmol Vis Sci. 2023;64(8):5433\u20135433.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"1329_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0269","volume":"5","author":"J Gomez Rossi","year":"2022","unstructured":"Gomez Rossi J, Rojas-Perilla N, Krois J, Schwendicke F. Cost-effectiveness of artificial intelligence as a decision-support system applied to the detection and grading of melanoma, dental caries, and diabetic retinopathy. JAMA Netw Open. 2022;5(3):e220269.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1329_CR50","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s40123-023-00688-y","volume":"12","author":"A Srisubat","year":"2023","unstructured":"Srisubat A, Kittrongsiri K, Sangroongruangsri S, Khemvaranan C, Shreibati JB, et\u00a0al. Cost-utility analysis of deep learning and trained human graders for diabetic retinopathy screening in a nationwide program. Ophthalmol Ther. 2023;12(2):1339\u201357.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1329_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00785-z","volume":"6","author":"R Channa","year":"2023","unstructured":"Channa R, Wolf RM, Abr\u00e0moff MD, Lehmann HP. Effectiveness of artificial intelligence screening in preventing vision loss from diabetes: a policy model. NPJ Digit Med. 2023;6(1):53.","journal-title":"NPJ Digit Med"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01329-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01329-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01329-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:26:59Z","timestamp":1773156419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01329-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01329-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Firas Rahhal is a consultant for Boehringer Ingelheim. Jun Zhang and Munia Mukherjee are employees of Boehringer Ingelheim Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors; therefore, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}